Actinogen Medical Ltd
ASX:ACW

Watchlist Manager
Actinogen Medical Ltd Logo
Actinogen Medical Ltd
ASX:ACW
Watchlist
Price: 0.048 AUD -4% Market Closed
Market Cap: 152.8m AUD

Operating Margin

-2 140.5%
Current
Improving
by 1 680.3%
vs 3-y average of -3 820.8%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-2 140.5%
=
Operating Income
AU$-14.7m
/
Revenue
AU$685.3k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-2 140.5%
=
Operating Income
AU$-14.7m
/
Revenue
AU$685.3k

Peer Comparison

Country Company Market Cap Operating
Margin
AU
Actinogen Medical Ltd
ASX:ACW
152.5m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.7B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 81% of companies in Australia
Percentile
19th
Based on 3 951 companies
19th percentile
-2 140.5%
Low
-14 949 200% — -526.4%
Typical Range
-526.4% — 6.1%
High
6.1% — 145 596.9%
Distribution Statistics
Australia
Min -14 949 200%
30th Percentile -526.4%
Median -25.2%
70th Percentile 6.1%
Max 145 596.9%

Actinogen Medical Ltd
Glance View

Market Cap
152.8m AUD
Industry
Biotechnology

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in developing treatment for cognitive impairment associated with neurological diseases of raised cortisol levels inside brain cells. The firm's lead drug candidate, Xanamem, has been designed to block the production of cortisol the stress hormone in the brain. Xanamem is a unique inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the central nervous system. The company is an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in neuropsychiatric diseases. The firm focuses on developing Phase II clinical trial evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer’s disease.

ACW Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-2 140.5%
=
Operating Income
AU$-14.7m
/
Revenue
AU$685.3k
What is Actinogen Medical Ltd's current Operating Margin?

The current Operating Margin for Actinogen Medical Ltd is -2 140.5%, which is above its 3-year median of -3 820.8%.

How has Operating Margin changed over time?

Over the last 3 years, Actinogen Medical Ltd’s Operating Margin has increased from -23 095.6% to -2 140.5%. During this period, it reached a low of -23 095.6% on May 30, 2022 and a high of -2 140.5% on Jul 30, 2025.

Back to Top